PATIENT WEBSITE

FOR us HEALTHCARE professionals only



Dolphin image for AKYNZEO

One dose* for 5 days of CINV prevention

SEE DOSING

Safety and efficacy proven through multiple cycles of chemotherapy

SEE DETAILS

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Netupitant/palonosetron (AKYNZEO®) plus dexamethasone is recommended in the NCCN Guidelines as an option (Category 1) for CINV prevention in both HEC and MEC†1

To help identify patients at greatest risk for emesis (>90% frequency of emesis) from intravenous antineoplastic agents‡§
  • AC combination (any chemotherapy
    regimen that contains an anthracycline and cyclophosphamide)
  • Carboplatin AUC ≥4
  • Carmustine (>250 mg/m2)
  • Cisplatin
  • Cyclophosphamide (>1500 mg/m2)
  • Dacarbazine
  • Doxorubicin (≥60 mg/m2)
  • Epirubicin (>90 mg/m2)
  • Ifosfamide (≥2 g/m2 per dose)
  • Mechlorethamine
  • Streptozocin
To help identify patients at moderate risk for emesis (>30%-90% frequency of emesis) from intravenous antineoplastic agents‡§
  • Aldesleukin (>12-15 million IU/m2)
  • Amifostine (>300 mg/m2)
  • Arsenic trioxide
  • Azacitidine
  • Bendamustine
  • Busulfan
  • Carboplatin AUC <4||
  • Carmustine (≤250 mg/m2)||
  • Clofarabine
  • Cyclophosphamide (≤1500 mg/m2)
  • Cytarabine (>200 mg/m2)
  • Dactinomycin||
  • Daunorubicin||
  • Dinutuximab
  • Doxorubicin (<60 mg/m2)||
  • Epirubicin (<90 mg/m2)||
  • Idarubicin
  • Ifosfamide (<2 g/m2 per dose)||
  • Interferon alfa (≥10 million IU/m2)
  • Irinotecan||
  • Melphalan
  • Methotrexate (≥250 mg/m2)||
  • Oxaliplatin||
  • Temozolomide
  • Trabectedin||
  • In clinical studies for AKYNZEO, cancer patients received cisplatin-based highly emetogenic chemotherapy (median dose=75 mg/m2)2

One dose* for 5 days of CINV prevention

SEE DOSING

Safety and efficacy proven through multiple cycles of chemotherapy

SEE DETAILS
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed May 11, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. AKYNZEO® (netupitant/palonosetron) capsules Full Prescribing Information.